Search
Foralumab
go.drugbank.com/drugs/DB16170InvestigationalForalumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Dihydroxyacetone phosphate
go.drugbank.com/drugs/DB04326InvestigationalDihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.
Fleroxacin
go.drugbank.com/drugs/DB04576ExperimentalFleroxacin is not an inhibitor of CYP1A2.[A39048]
Zoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigationalGonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesQR-333
go.drugbank.com/drugs/DB05533Investigationalconcentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder that can
Etizolam
go.drugbank.com/drugs/DB09166InvestigationalIt is an agonist at GABA-A receptors and possesses amnesic, anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMMDA
go.drugbank.com/drugs/DB01442ExperimentalIllicitIt also acts as an entheogen and an entactogen. MMDA bears resemblance to the psychopharmacologically active essential oils elemicin and myristicin found in nutmeg.
VSF-173
go.drugbank.com/drugs/DB05753InvestigationalVSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect.